An Evaluation of NGM120 in a Randomized, Double-blind, Placebo-controlled Study in Participants With Colorectal Cancer Who Have Cancer Cachexia.
Sponsor: NGM Biopharmaceuticals, Inc
ClinicalTrials ID:NCT07033026
This Phase 2 study evaluates the efficacy, safety, and tolerability of NGM120 in colorectal cancer patients with cachexia. Participants must have a documented diagnosis and meet Fearon criteria for weight loss. Interventions include NGM120 administered subcutaneously every 4 or 8 weeks, or a placebo every 4 weeks. Informed consent is required.
Patient Parameters
| Parameter | Options |
|---|
Program Overview
A multi-center evaluation of NGM120 in a randomized, double-blind, placebo-controlled study in participants with colorectal cancer who have cancer cachexia.
Description
Evaluation of Efficacy, Safety and Tolerability of NGM120 in a Phase 2, Randomized, Double-blind, Placebo-controlled, Multi-center Study in Participants with Colorectal Cancer who have Cancer Cachexia
Eligibility Criteria
Inclusion Criteria
- Documented active diagnosis of colorectal cancer.
- Cachexia defined by Fearon criteria of weight loss.
- Signed informed consent.
Exclusion Criteria
- Current active reversible causes of decreased food intake.
- Receiving tube feedings or parenteral nutrition at the time of Screening or Randomization.
- Have cachexia caused by other reasons.
Locations
| FACILITY | ZIP | CITY | STATE |
|---|---|---|---|
| NGM Clinical Study Site | 78041 | Laredo | Texas |
Get This Program In Your Inbox
You can sign up and apply your patients for this program.